These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
527 related articles for article (PubMed ID: 23557867)
1. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Li DY; Teng RC; Zhu HJ; Fang Y Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867 [TBL] [Abstract][Full Text] [Related]
2. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827 [TBL] [Abstract][Full Text] [Related]
3. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247 [TBL] [Abstract][Full Text] [Related]
4. Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients. Xin HW; Liu HM; Li YQ; Huang H; Zhang L; Yu AR; Wu XC Int J Clin Pharmacol Ther; 2014 Jun; 52(6):497-503. PubMed ID: 24691060 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients. Liu F; Ou YM; Yu AR; Xiong L; Xin HW Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481 [TBL] [Abstract][Full Text] [Related]
6. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093 [TBL] [Abstract][Full Text] [Related]
7. [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients]. Zhu L; Song HT; Wang QH; Wu WZ; Yang SL; Tan JM Yao Xue Xue Bao; 2012 Jul; 47(7):878-83. PubMed ID: 22993851 [TBL] [Abstract][Full Text] [Related]
8. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697 [TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368 [TBL] [Abstract][Full Text] [Related]
10. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X Gene; 2022 Jan; 809():146007. PubMed ID: 34688813 [TBL] [Abstract][Full Text] [Related]
11. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586 [TBL] [Abstract][Full Text] [Related]
13. CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Tao XR; Xia XY; Zhang J; Tong LY; Zhang W; Zhou X; Liu ZH; Song HT Eur J Pharm Sci; 2015 Aug; 76():238-44. PubMed ID: 25976223 [TBL] [Abstract][Full Text] [Related]
15. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629 [TBL] [Abstract][Full Text] [Related]
16. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094 [TBL] [Abstract][Full Text] [Related]
17. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920 [TBL] [Abstract][Full Text] [Related]
18. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257 [TBL] [Abstract][Full Text] [Related]
19. Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. Liu X; Li J; Fu Q; Liu S; Zhang Y; Wang X; Wang H; Li J; Zhu C; Wang C; Huang M Drug Metab Dispos; 2015 Apr; 43(4):455-8. PubMed ID: 25587129 [TBL] [Abstract][Full Text] [Related]
20. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]